RxDoctor Payments DataLook up a doctor →

Nicole Seminara, MD

Dermatology · Huntersville, NCNPI 1437441003

Payments from drug & device makers

$2,145,157in general payments, 2019–2025

Across 2,070 payments — averaging $1036.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$571K
  • Johnson & Johnson$351K
  • Janssen Research & Development, LLC$193K
  • Novartis$170K
  • Lilly USA, LLC$154K
  • Eli Lilly$131K
  • plus $575K from 29 others
$12,341in research payments, 2019–2025

Across 2 payments — averaging $6170.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$12K

What the payments were for

  • Consulting fees$132,0779%
  • Speaking & faculty fees$1,136,46680%
  • Travel & lodging$113,7558%
  • Food & beverage$37,9123%
  • Education$3720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,145,157 in reported general payments places this provider in the 95th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$589,518
Medicare patients
974
Services billed
7,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib46$296,888
Cosentyx Unoready PenSecukinumab12$166,558
TremfyaGuselkumab11$146,328
Dupixent PenDupilumab36$141,671
HumiraAdalimumab11$74,181
Dupixent SyringeDupilumab14$53,831
Clobetasol Propionate120$6,293
Tacrolimus21$3,094
Doxycycline Hyclate134$3,076
Triamcinolone Acetonide237$2,846
Fluorouracil24$2,148
Desonide36$1,962
Finasteride181$1,510
Dutasteride53$1,486
Metronidazole29$1,448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$570,770$371,06957 claims
Johnson & JohnsonTremfya$350,985$146,32811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →